PharmaCielo Signs Pan-European Distribution Agreement for CBD Isolate and Broad-Spectrum CBD Oil

Published: January 27, 2020

PharmaCielo Signs Pan-European Distribution Agreement for CBD Isolate and Broad-Spectrum CBD Oil

PharmaCielo Ltd., the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., has signed a three-year pan-European distribution agreement (the “Agreement”), in which the Company’s high-grade CBD isolate and broad-spectrum CBD oil will be sold to wholesalers and medicinal CPG product manufacturers through GMP certified lab owner, CBD Export Global.

The Agreement with the Quebec, Canada-based CBD Export Global expands PharmaCielo’s distribution network in Europe with shipments into the EU to commence in 2020 with increased volumes during the duration of the agreement as B2B markets are expanded.  A minimum target volume of 2,000 kg has been agreed to in the first year of the three-year performance-based Agreement, allowing for confirmation of individual market regulatory approvals and enabling increased sales volume expansion in subsequent years.

“The agreement with CBD Export Global is part of PharmaCielo’s second-phase growth strategy complementing the first phase in which we established one of the largest cultivation and extraction operations in Colombia and initiated global sales, and now in the second phase expanding the distribution network as production volumes increase on a daily basis to take our high-quality medicinal CBD extracts to global markets,” said David Attard, Chief Executive Officer of PharmaCielo. “In 2019 we saw global demand for quality medicinal extracts increasing on an ongoing basis. In 2020 we are further expanding our distribution and sales channels. The collaboration with CBD Export Global will play a key role in our continued growth.”

The distribution agreement with CBD Export Global is entered into with the intent of continued market expansion beyond 2019’s experience successfully completing commercial shipments of CBD isolate from PharmaCielo to the U.S. and Switzerland.

“As a fellow Canadian company helping to build a global industry, we are delighted to build a relationship with PharmaCielo as we access the global industry for the very best of both product supply and, with recognition of their position as the first and only global GAP certified cannabis supply chain from Colombia to Europe, the ability to meet the needs of a demanding global medicinal marketplace,” says Alex Grenier, Chief Executive Officer of CBD Export Global.

CBD Export Global is focused on establishing the market standard in originating, handling, processing and marketing a wide range of cannabis derivatives to downstream manufacturers of products – including the processing industry (medical, cosmetic, animal and consumer products), local importers and government purchasing bodies. With its strategic network of assets and infrastructure, including its cGMP certified laboratory and strong relationships along the supply chain, CBD Export Global meets the needs of customers around the world.

Distribution by PharmaCielo into European countries under the Agreement is subject to the approval of the TSX Venture Exchange.

Recent News

View All News Items

Latest Article

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

The legalization of cannabis edibles, extracts and topicals will expand the cannabis market and create new opportunities for producers, innovators and investors. According to a recent report from Deloitte, the Canadian market for these new cannabis products is expected to be worth $2.7 billion annually, with edibles accounting for more than half ($1.6 billion).

 

Read Article